News & Events

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award

The Award to be presented at BIO-Europe conference in Munich, November 2015

Apply at

Berlin, July 30, 2015 – The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium, ENATRANS, have launched the second edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2015.

The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients.

The Award is open to companies as well as academic and private researchers across the globe. Nominated projects should be totally new diagnostic and therapeutic approaches that address unmet medical needs with nanomedicine, and have an explicit and defined potential market.

Nanomedicine proposals will be evaluated in two categories:

  • Best early clinical stage project Award
  • Best product or deal Award

Applications will be reviewed and assessed by a panel of highly-qualified pharma industry experts with experience in R&D and business roles: Patrick Boisseau, Business Development Nanomedicine at CEA- Leti and President of the ETPN; Patrick Tricoli, VP Corporate Development and CEO Nanobiotix Corp.; Jeff Hrkach, formerly Chief Technology Officer of BIND Therapeutics, Inc. and member of the Nanomedicines Alliance and Henry Havel, formerly Senior Research Fellow at Eli Lilly and Chairman of the Nanomedicines Alliance. For the first time in its history, ETPN gets together with the US-based Nanomedicines Alliance for a meaningful initiative.

The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, the Nanomedicines Alliance, the US-based consortium dedicated to promoting and facilitating the scientific advancement, regulatory approval, and public appreciation of nanotechnology-based medicines and Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Award ceremony will take place during BIO-Europe 2015 in Munich, Germany, on November the 3rd, 2015.

Winners will benefit from a full registration (including partnering) for BIO-Europe 2015 and a 10 minutes project presentation during the Conference. The winning projects will also be granted with a presentation during the ETPN General Assembly 2016, along with 1 year’s free ETPN membership and a consulting action by the experts from the Translation Advisory Board (TAB). The winners will gain visibility to EU decision makers from pharma industry, academia, finance and media.

Entries for nominations for the Award will be open until September 15, 2015. The application form is available online by clicking on this link


Created in 2005, the European Technology Platform for Nanomedicine is an initiative led by Industry and set up together with the European Commission to address the applications of nanotechnology to achieve breakthroughs in healthcare. The ETPN is structuring and federating the European Nanomedicine community and leading the communication toward the European Commission and the European Members States.


Enabling NAnomedicine TRANSlation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to Nanomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on Nanomedicine. ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).


The 21th annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,200 international decision makers from biotech, pharma and finance along with the most promising start-ups and emerging companies, representing upwards of 1,800 companies, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 2-4, 2015 in Munich, Germany.

Follow BIO-Europe 2015 on Twitter: (hashtag: #BEU15)



The Nanomedicines Alliance focuses on the global advancement of nanomedicines from research to commercialization, with the mission to promote and facilitate the scientific advancement, regulatory approval, and public appreciation of nanotechnology-based medicines world-wide for the diagnosis, treatment and prevention of disease.

Nanobiotix -

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma, locally advanced Head and Neck Cancer, Rectum cancer (PharmaEngine) and Liver cancers. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company Head Quarter is based in Paris, France. Affiliate in Cambridge United States.

EBD Group -

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma, medical device and related life science companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences, are run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, BioEquity Europe, ChinaBio® Partnering Forum, Medtech Partnering Forum and Biotech Showcase™.

EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information please contact:

back to news


Melanie Toyne-SewellManaging Partner